Q3 2026 13F filing
Updated 6 days ago80 disclosed positions worth $21B
Full holdings
Every line item disclosed in Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | I Incyte Corporation | $3.7B | 30.76M | 17.74% | — |
| 2 | B BeOne Medicines Ltd. | $3.2B | 8.83M | 15.36% | — |
| 3 | R Revolution Medicines, Inc. | $2.2B | 10.64M | 10.38% | — |
| 4 | K Kodiak Sciences Inc. | $2.1B | 21.86M | 9.85% | — |
| 5 | M Madrigal Pharmaceuticals, Inc. | $1.1B | 2.14M | 5.13% | — |
| 6 | I Insmed Incorporated | $1B | 8.80M | 4.77% | — |
| 7 | K Kymera Therapeutics, Inc. | $967.8M | 8.66M | 4.60% | — |
| 8 | A ACADIA Pharmaceuticals Inc. | $864.7M | 42.91M | 4.11% | — |
| 9 | G GRAIL, Inc. | $564.5M | 4.03M | 2.68% | — |
| 10 | S Summit Therapeutics Inc. | $554.4M | 32.79M | 2.63% | — |
| 11 | R Rhythm Pharmaceuticals, Inc. | $533.6M | 5.60M | 2.54% | — |
| 12 | P Praxis Precision Medicines, Inc. | $510.6M | 1.75M | 2.43% | — |
| 13 | A AbCellera Biologics Inc. | $481.6M | 33.01M | 2.29% | — |
| 14 | A Alkermes plc | $405.7M | 10.01M | 1.93% | — |
| 15 | C Celcuity Inc. | $383M | 4.82M | 1.82% | — |
| 16 | K Kiniksa Pharmaceuticals International, plc | $211.5M | 2.83M | 1.00% | — |
| 17 | I IDEAYA Biosciences, Inc. | $192.5M | 5.01M | 0.91% | — |
| 18 | E Edgewise Therapeutics, Inc. | $150.3M | 3.70M | 0.71% | — |
| 19 | Q Replimune Group, Inc. | $146.2M | 11.05M | 0.69% | — |
| 20 | R Roivant Sciences Ltd. | $133.9M | 3.66M | 0.64% | — |
| 21 | A Arrowhead Pharmaceuticals, Inc. | $111.9M | 1.71M | 0.53% | — |
| 22 | N Nurix Therapeutics, Inc. | $110.5M | 4.66M | 0.52% | — |
| 23 | I Immunovant, Inc. | $93.6M | 2.77M | 0.44% | — |
| 24 | C Celldex Therapeutics, Inc. | $83.1M | 2.56M | 0.40% | — |
| 25 | D Denali Therapeutics Inc. | $77.2M | 3.73M | 0.37% | — |
| 26 | D Dianthus Therapeutics, Inc. | $75M | 852.2K | 0.36% | — |
| 27 | C Celcuity Inc. | $55.5M | 30.75M | 0.26% | — |
| 28 | R Rapport Therapeutics, Inc. | $52M | 1.55M | 0.25% | — |
| 29 | M Monte Rosa Therapeutics, Inc. | $51.8M | 4.35M | 0.25% | — |
| 30 | R Relay Therapeutics, Inc. | $51M | 2.83M | 0.24% | — |
| 31 | I Ionis Pharmaceuticals, Inc. | $45.7M | 1.02M | 0.22% | — |
| 32 | G Structure Therapeutics Inc. | $44.8M | 1.43M | 0.21% | — |
| 33 | E Enliven Therapeutics, Inc. | $41.5M | 905.2K | 0.20% | — |
| 34 | B Bicycle Therapeutics plc | $40.1M | 10.89M | 0.19% | — |
| 35 | P Prelude Therapeutics Inc. | $39.6M | 10.12M | 0.19% | — |
| 36 | M Mirum Pharmaceuticals, Inc. | $38.1M | 446.0K | 0.18% | — |
| 37 | D Design Therapeutics, Inc. | $37.6M | 2.99M | 0.18% | — |
| 38 | I Immatics N.V. | $37.4M | 4.26M | 0.18% | — |
| 39 | S Stoke Therapeutics, Inc. | $34.2M | 1.31M | 0.16% | — |
| 40 | T Entrada Therapeutics, Inc. | $32.2M | 5.07M | 0.15% | — |
| 41 | N Neurogene Inc. | $27.6M | 991.7K | 0.13% | — |
| 42 | X Xencor, Inc. | $27.5M | 1.10M | 0.13% | — |
| 43 | F Faeth Therapeutics, Inc. | $23.9M | 803.4K | 0.11% | — |
| 44 | A Absci Corporation | $23M | 2.13M | 0.11% | — |
| 45 | I Disc Medicine, Inc. | $22.9M | 349.7K | 0.11% | — |
| 46 | R Arcus Biosciences, Inc. | $21.8M | 844.8K | 0.10% | — |
| 47 | G Generate Biomedicines, Inc. | $21.4M | 1.42M | 0.10% | — |
| 48 | T Taysha Gene Therapies, Inc. | $19.5M | 4.00M | 0.09% | — |
| 49 | A Aktis Oncology, Inc. | $19.4M | 996.4K | 0.09% | — |
| 50 | J Jade Biosciences, Inc. | $17.3M | 1.23M | 0.08% | — |